Apoptosis Inhibitor of Macrophage, Monocyte Chemotactic Protein-1, and C-Reactive Protein Levels Are Increased in Patients with Metabolic Syndrome: A Pilot Study

Savas E. M., Oguz S. H., Samadi A., YILMAZ IŞIKHAN S., ÜNLÜTÜRK U., LAY İ., ...More

METABOLIC SYNDROME AND RELATED DISORDERS, vol.18, no.4, pp.197-205, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1089/met.2019.0074
  • Journal Name: METABOLIC SYNDROME AND RELATED DISORDERS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.197-205
  • Keywords: AIM, MCP-1, CRP, macrophage, metabolic syndrome, inflammation, cut off point, OBSTRUCTIVE SLEEP-APNEA, CHEMOATTRACTANT PROTEIN-1, ADIPOSE-TISSUE, INSULIN-RESISTANCE, DIAGNOSTIC MARKER, ABDOMINAL OBESITY, MCP-1, AIM, ACTIVATION, CELLS
  • Hacettepe University Affiliated: Yes

Abstract

Background: Apoptosis inhibitor of macrophage (AIM) and monocyte chemotactic protein-1 (MCP-1) are molecules that cause migration of M1 macrophages to visceral adipocytes, which is the first step in development of metabolic syndrome. The aim of this study is to evaluate the status of AIM and MCP-1 in metabolic syndrome and to investigate their use as biomarkers.